SCHEMBL21775802

SCHEMBL21775802

COC(=O)c1cccc(N(C)C)c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.53
TSHR P16473 2/20 0.52
LMNA P02545 1/20 0.52
ALDH1A1 P00352 3/20 0.48
MAPT P10636 3/20 0.48
GAA P10253 2/20 0.48
TP53 P04637 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HSD17B10 Q99714 2/20 0.46
CFTR P13569 1/20 0.46
CA1 P00915 4/20 0.46
CA2 P00918 4/20 0.46
CA9 Q16790 4/20 0.46
CA12 O43570 3/20 0.46
CA7 P43166 3/20 0.46
CA14 Q9ULX7 3/20 0.46
KDM4E B2RXH2 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
CXCR2 P25025 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29408467 0.83 KMT2A (0.67) KMT2ATSHRLMNAALDH1A1MAPT
SCHEMBL43644 0.83 KMT2A (0.67) KMT2ATSHRLMNAALDH1A1MAPT
SCHEMBL1538293 0.82 TSHR (0.65) KMT2ATSHRLMNAALDH1A1MAPT
SCHEMBL2427326 0.82 KMT2A (0.53) KMT2ATSHRLMNAALDH1A1MAPT
SCHEMBL24572151 0.82 KMT2A (0.53) KMT2ATSHRLMNAALDH1A1MAPT
SCHEMBL6733366 0.81 ALDH1A1 (0.53) KMT2ATSHRLMNAALDH1A1MAPT
SCHEMBL4463760 0.81 KMT2A (0.51) KMT2ATSHRLMNAALDH1A1MAPT
SCHEMBL31620809 0.81 KMT2A (0.51) KMT2ATSHRLMNAALDH1A1MAPT
SCHEMBL25208675 0.81 KMT2A (0.51) KMT2ATSHRLMNAALDH1A1MAPT
SCHEMBL729589 0.79 ALDH1A1 (0.57) KMT2ATSHRALDH1A1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11692004-B2 Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof JIANGSU VANGUARD PHARMACEUTICAL CO., LTD. (CN) 2023-07-04 US disclosed
US-11692004-B2 Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof JIANGSU VANGUARD PHARMACEUTICAL CO., LTD. (CN) 2023-07-04 US disclosed
WO-2020038279-A1 SUBSTITUTED PYRAZOLE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF 天津谷堆生物医药科技有限公司 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11692004-B2 Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof FARS2, GOT2, HADHB KMT2A 4665/4885TSHR 4169/4885LMNA 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.